Global Retirement Partners LLC grew its holdings in Sanofi (NASDAQ:SNY – Free Report) by 15.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,315 shares of the company’s stock after purchasing an additional 834 shares during the period. Global Retirement Partners LLC’s holdings in Sanofi were worth $364,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the business. Mezzasalma Advisors LLC increased its holdings in shares of Sanofi by 3.0% in the 3rd quarter. Mezzasalma Advisors LLC now owns 10,234 shares of the company’s stock valued at $590,000 after purchasing an additional 294 shares during the period. Probity Advisors Inc. increased its holdings in shares of Sanofi by 4.9% in the 3rd quarter. Probity Advisors Inc. now owns 14,413 shares of the company’s stock valued at $831,000 after purchasing an additional 671 shares during the period. Leisure Capital Management increased its holdings in shares of Sanofi by 6.0% in the 3rd quarter. Leisure Capital Management now owns 17,870 shares of the company’s stock valued at $1,030,000 after purchasing an additional 1,010 shares during the period. Stillwater Capital Advisors LLC acquired a new position in shares of Sanofi in the 3rd quarter valued at about $208,000. Finally, Opal Wealth Advisors LLC increased its holdings in Sanofi by 11.7% in the third quarter. Opal Wealth Advisors LLC now owns 5,127 shares of the company’s stock worth $295,000 after buying an additional 538 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.
Sanofi Stock Down 2.3 %
SNY opened at $53.66 on Tuesday. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $136.16 billion, a price-to-earnings ratio of 29.16, a P/E/G ratio of 1.57 and a beta of 0.60. The business has a 50 day moving average of $56.13 and a 200-day moving average of $51.62.
Analyst Upgrades and Downgrades
A number of research firms recently commented on SNY. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.
View Our Latest Stock Analysis on SNY
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
- Five stocks we like better than Sanofi
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Investing In Preferred Stock vs. Common Stock
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.